Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe.

Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and support TruePrime products for primer-free WGA as well as SunScript thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology in the UK and Ireland. Both are powerful tools addressing key challenges in next-generation sequencing (NGS) and single cell analysis (SCA).

TruePrime is based on Sygnis’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.

ADVERTISEMENT

On the other hand, the product line of Sygnis’ SunScript covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the fastest and most thermostable enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling many downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.

With more than 4,000 companies, employing around 160,000 people and with a total annual turnover of over €68Bn, the UK life science industry can be considered one of the world leaders. This agreement with Cambridge Bioscience, a leading UK based distributor of cutting-edge life science research products, represents a huge step forward for the Germany and Spain- based company.

Last December, Sygnis already conclude the same agreement with Biocat to distribute TruePrime through Germany. Sygnis seems to be building a complete network of distribution in Europe. Who will be the next partner?

Previous post

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Next post

Karolinska Development took a Step Back in its Biotech portfolio

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.